美国慢性肾脏病患者肺炎球菌疫苗接种的成本效果分析
该研究采用Markov模型评估美国50-79岁人群按CKD风险分层接种肺炎球菌疫苗的成本效果,发现各层均具成本效果,50-64岁CKD患者增量成本效果比随CKD严重度增加而降低,支持扩大该人群接种指征。
要点
- 65-79岁和50-64岁接种总体具成本效果,ICER分别为15000和38000美元/QALY。
- 50-64岁肾衰竭或肾病范围蛋白尿者ICER最低为1000美元/QALY。
- 50-64岁CKD患者接种在最低疫苗效力或成本增50%假设下仍具成本效果。
核心结论
- 肺炎球菌疫苗接种在65-79岁和50-64岁成人中总体具成本效果。
- 50-64岁CKD患者接种具成本效果,支持扩大指征至较轻CKD人群。
研究设计与样本
- 成本效果分析,Markov模型,美国卫生部门视角,终身时间跨度。
- 人群为美国50-64岁和65-79岁成人,按CKD风险分层:无CKD、中度风险CKD、高风险CKD、肾衰竭或肾病范围蛋白尿。
主要发现
- NHANES 1999-2004疫苗接种率:65-79岁56.6%,50-64岁有指征28.5%,无指征9.7%,各CKD风险层相似。
- 65-79岁ICER为15000美元/QALY,50-64岁为38000美元/QALY,均低于100000美元/QALY阈值。
- 50-64岁各层ICER:肾衰竭或肾病范围蛋白尿1000美元/QALY,高风险CKD 17000美元/QALY,中度风险CKD 25000美元/QALY,无CKD 43000美元/QALY。
关键数值与推荐
- 成本效果阈值定义为<100000美元/QALY。
- CKD分层标准:无CKD为eGFR≥60mL/min/1.73m2且UACR<30mg/g;肾衰竭为eGFR<15mL/min/1.73m2或UACR≥2000mg/g。
临床怎么用
- 应普遍提高肺炎球菌疫苗接种率。
- 可考虑将接种指征扩大至50-64岁较轻CKD患者。
局限性
- 部分模型参数基于一般人群数据。
- 分析未考虑肾脏疾病进展相关成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Pneumococcal vaccine is recommended for adults 65 years and older and those younger than 65 years with clinical indications (eg, diabetes, lung/heart disease, kidney failure, and nephrotic syndrome). Its cost-effectiveness in less severe chronic kidney disease (CKD) is uncharacterized. STUDY DESIGN: Cost-effectiveness analysis. SETTING & POPULATION: US adults aged 50 to 64 and 65 to 79 years stratified by CKD risk status: no CKD (estimated glomerular filtration rate≥60mL/min/1.73m2 and urinary albumin-creatinine ratio<30mg/g), CKD with moderate risk, CKD with high risk, and kidney failure (estimated glomerular filtration rate<15mL/min/1.73m2) or nephrotic-range albuminuria (urinary albumin-creatinine ratio≥2,000mg/g). Data sources were the National Health and Nutrition Examination Survey (NHANES) 1999 to 2004, Centers for Disease Control and Prevention, and the Atherosclerosis Risk in Communities (ARIC) Study. INTERVENTION(S): Vaccination compared to no vaccination. OUTCOMES: Incremental cost-effectiveness ratios based on US dollars per quality-adjusted life-year (QALY). MODEL, PERSPECTIVE, & TIMEFRAME: Markov model, US health sector perspective, and lifetime horizon. RESULTS: The prevalence of pneumococcal vaccination in NHANES 1999 to 2004 was 56.6% (aged 65-79 years), 28.5% (aged 50-64 years with an indication), and 9.7% (aged 50-64 years without an indication), with similar prevalences across CKD risk status. Pneumococcal vaccination was overall cost-effective (<US $100,000/QALY) for adults aged 65 to 79 years (US $15,000/QALY) and 50 to 64 years (US $38,000/QALY). Among those aged 50 to 64 years, incremental cost-effectiveness ratios were lowest for kidney failure or nephrotic-range albuminuria (US $1,000/QALY), followed by CKD with high risk (US $17,000/QALY), CKD with moderate risk (US $25,000/QALY), and no CKD (US $43,000/QALY). Pneumococcal vaccination was cost-effective among adults aged 50 to 64 years with CKD even when assuming the lowest vaccine efficacy or 50% higher vaccine costs. LIMITATIONS: Some model parameters were based on data from the general population. Analysis did not consider costs associated with kidney disease progression. CONCLUSIONS: Uptake of pneumococcal vaccination should be improved in general. Our results also suggest the cost-effectiveness of expanding its indication to younger adults with CKD less severe than kidney failure or nephrotic syndrome.
引用
- Ishigami J, Padula WV, Grams ME, et al. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States. Am J Kidney Dis. 2019. PMID: 30898360. doi:10.1053/j.ajkd.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。